B. Cochrane

Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy.

Do-Hoon Kim, T. Whelan, A. Nichol, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study

G. Pond, S. Chia, M. Clemons, 2015, Journal of bone oncology.

Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.

G. Pond, A. Robidoux, S. Chia, 2013 .

Interim Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation (APBI) Using 3D Conformal External Beam Radiation Therapy (3D CRT)

T. Whelan, I. Olivotto, P. Truong, 2013 .

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

G. Pond, A. Robidoux, S. Chia, 2014, Breast Cancer Research and Treatment.